Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 332

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 332
---
writers who may act solely as agents at market prices prevailing at the time of
sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of our
common stock offered by this prospectus could be effected in one or more of the following methods:

| · | ordinary brokerage transactions; |

| · | transactions involving cross or block trades; |

| · | through brokers, dealers, or underwriters who may act solely as agents; |

| · | “at the market” into an existing market for our securities; |

| · | in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected 
 through agents;                                                                                                                   |

| · | in privately negotiated transactions; or |

| · | any combination of the foregoing. |

In order to comply with the
securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition,
in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from
the state’s registration or qualification requirement is available and complied with.

The Selling Shareholder is
an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act.

The Selling Shareholder has
informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our Depositary Shares that
it has acquired and may in the future acquire from us pursuant to the Purchase Agreement. Such sales will be made at prices and at terms
then prevailing or at prices related to the then current market price. Each such registered broker-dealer will be an underwriter within
the meaning of Section 2(a)(11) of the Securities Act. The Selling Shareholder has informed us that each such broker-dealer will receive
commissions from the Selling Shareholder that will not exceed customary brokerage commissions.

Brokers, dealers, underwriters
or agents participating in the distribution of our Depositary Shares offered by this prospectus may receive compensation in the form of
commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling
Shareholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of our Depositary
Shares sold by the Selling Shareholder may be less than or in excess of customary